Sun Pharmaceutical Industries Ltd. Share Price

Zydus completes Sterling Biotech API business buy

Zydus Lifesciences Limited (ZYDUSLIFE) has completed the acquisition of the API business of Sterling Biotech Limited. The deal follows completion of conditions precedent and closing date adjustments. The acquisition is based on the Business Transfer Agreement dated September 17, 2024. The transaction transfers the API business of Sterling Biotech to Zydus Lifesciences. The company has confirmed the closing of the deal after fulfilling all required conditions under the agreement. The key triggers are the completion of the Sterling Biotech API business acquisition and the fulfilment of conditions under the September 2024 agreement. This strengthens Zydus’s API manufacturing capabilities and product portfolio in fermentation-based ingredients. Peers such as Sun Pharma, Divi's Laboratories and Laurus Labs may face comparison on API capacity and backward integration. Near-term prices could react positively to the successful closure of the long-pending deal. Risks include integration challenges or slower-than-expected contribution from the acquired assets. Competitors listed: Sun Pharma, Divi's Laboratories, Laurus Labs. We have no financial interest in this news.

See More

Sensex Opens 600 Points Higher; IndiGo Leads Gains

Sensex open: It opened up 595 points (0.79%) at 76,288.65, against Monday’s close of 75,692.78. Nifty open: The Nifty50 opened up 141 points (0.60%) at 23,582.25, against a close of 23,440.80. Early trade: By 9:29 AM the Sensex was at 76,397.72, up 704.94 points (0.93%), and the Nifty was up about 176 points, above 23,600. Streak: This is the fourth straight session of gains. Over the last two sessions the Sensex has added 1,938 points (2.6%) and the Nifty 565 points (2.45%). Top gainer: InterGlobe Aviation (IndiGo) led the Nifty50, up 2.95% to ₹5,064.80 from ₹4,919.90. Other gainers: Asian Paints, Bajaj Finance, Shriram Finance, ICICI Bank and HDFC Bank were also leading the early gains. Top loser:

was the top Nifty50 loser, down 1.78% to ₹230.64. Other losers: In the Sensex pack, Trent, BEL, Power Grid, Sun Pharma and NTPC were among the biggest losers. Drivers: Cooling crude oil, FII buying, steady US Treasury yields and strong earnings supported the open, even though Wall Street fell overnight (Nasdaq down 1.39%).

See More

Sun Pharma slips 2% as Ilumya sales slow in Q2

Limited (SUNPHARMA) traded 1.6% lower at ₹1,749.80 on November 2 after management flagged slower sales of its key specialty drug Ilumya. Reported Q2 FY27 net profit fell 36% to ₹1,988.5 crore, announced on October 30. Revenue grew 11.9% to ₹16,198.7 crore, led by a 17.3% rise in India formulations. US formulation sales fell 8.3%. Profit was hit by ₹1,268.8 crore of one-time charges linked to a US antitrust settlement and the pending Organon acquisition. Adjusted profit rose 1.4% to ₹3,162 crore. The one-time charges explain the headline fall, not the business. The India business is growing strongly, and gross margin improved to 80.8% from 79.3%. Management also reiterated its high single-digit growth guidance for FY27, and 35 of 40 analysts covering the stock rate it a Buy. The concern is Ilumya, which made up 12% of FY26 sales. Its slowdown, along with falling US sales, is squeezing margins. EBITDA grew only 4.8%, and the EBITDA margin slipped to 29.3% from 31.3%. Emkay cut its target to ₹2,000. Investors should watch Ilumya’s psoriatic arthritis launch in November, US sales trends and the Organon deal closing. The key question is whether Ilumya can regain growth fast enough to protect margins. Disclosure: I do not hold any position in Sun Pharmaceutical Industries Limited. This post is for informational purposes only and is not investment advice.

See More

Sun Pharma Shares Drop 3% After Sharp Q2 Profit Decline

Sun Pharmaceutical Industries fell over 3% on Monday, snapping a four-day winning streak, after the company reported a steep drop in its July-September quarter ***** net profit plunged 36.36% year-on-year to ₹1,988.53 crore. The decline was largely due to one-time costs related to the proposed Organon acquisition and litigation expenses in the US. Revenue, however, rose nearly 24% to ₹16,198.71 crore, driven by strong performance in the India formulations business, which grew 17.3% to ₹5,552.3 crore and contributed 34.5% of total sales. Global innovative medicines sales also rose 6.9%.Management retained its high single-digit revenue growth guidance for FY27. Despite the weak profit numbers, most brokerages remained positive on the stock, citing the strength of the India business and long-term benefits from the Organon deal.

See More

Sensex Jumps 1,233 Points; Reliance Surges 11.6%

Sensex close: It ended at 75,692.78, up 1,233.25 points (about 1.7%), against Friday’s close of 74,459.53. Nifty close: The Nifty50 closed at 23,440.80, up 387.70 points (1.68%), after an intraday low of 23,207.05. Streak: This is the third straight gain, after rises on Thursday and Friday. Top gainer:

led the Nifty50, up 11.60% to ₹1,300.00 on strong earnings. Other gainers: Tata Steel (+5.83% to ₹177.37) and JSW Steel (+5.13% to ₹1,309.90) followed, with Shriram Finance and Coal India also among the leaders. Top loser: Infosys fell the most, down 2.03% to ₹1,161.00. Other losers: ICICI Bank and Dr Reddy’s were also among the biggest losers, and another source listed Adani Ports, Sun Pharma, Axis Bank and HDFC Life. Sectors: Energy, PSU banks, consumer durables, infra, auto and oil & gas rose 1-4.6%, while IT, media and pharma fell about 0.5% each. Broader market: The Nifty Midcap index rose 1% and the Smallcap index 0.7%. Drivers: Falling oil prices and strong earnings from heavyweights, especially Reliance, strengthened sentiment.

See More

Pharmaceutical Sector : Sun Pharmaceutical Industries Ltd.

Understanding Earnings Volatility in Pharma Sun Pharmaceutical Industries Ltd.

is one of India's leading pharmaceutical companies, with substantial domestic and international operations. The company's consolidated net profit declined 36% year-on-year to ₹1,989 crore for the September quarter, compared with ₹3,118 crore in the year-ago period, as reported in today's market coverage. Investors should investigate the reasons behind the decline, including exceptional items, product mix, regulatory developments, research costs and market-specific performance. Pharmaceutical analysis should combine financial performance with product launches, regulatory approvals, research pipelines and competitive pressures.

See More